The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs

The value of PFS36 as a primary endpoint for radiotherapy trials in patients with LACC: individual patient data from the Chinese NCC and validation from 26 RCTs

Objective: A conventional endpoint for locally advanced cervical cancer (LACC) clinical trials is overall survival (OS) with five years of follow-up. The primary hypothesis was that progression-free survival (PFS) with three years of follow-up (PFS36) would be an appropriate primary surrogate endpoi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xi Yang, Yuanyuan Zhang, Shuangzheng Jia, Yong Yang, Jie Zhu, Wei Li, Lingying Wu, Jusheng An, Manni Huang
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Journal of the National Cancer Center
Subjects:
Locally advanced cervical cancer
Radiotherapy
Surrogate endpoint
Progression-free survival
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2667005424001236
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2667005424001236

Similar Items